Insider Buying: Dominari (NASDAQ:DOMH) President Acquires 50,000 Shares

Key Points

• Dominari President Kyle Michael Wool purchased 50,000 shares at an average price of $2.02, investing $101,000 and increasing his direct stake by 1.19% to approximately 4.26 million shares.
• Dominari reported a quarterly loss of $0.21 per share, beating estimates of a $0.34 loss, while revenue totaled $16.79 million. Despite the earnings beat, the company posted negative profitability metrics.
• The stock opened at $2.18 and has traded between $1.91 and $8.40 over the past year. Analysts maintain a consensus “Sell” rating, while institutional investors own 42.48% of the company.

Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) President Kyle Michael Wool bought 50,000 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was bought at an average cost of $2.02 per share, with a total value of $101,000.00. Following the transaction, the president directly owned 4,261,828 shares in the company, valued at approximately $8,608,892.56. The trade was a 1.19% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Dominari Stock Performance

Shares of Dominari stock opened at $2.18 on Monday. Dominari Holdings Inc. has a 1 year low of $1.91 and a 1 year high of $8.40. The firm's 50-day simple moving average is $2.56 and its 200-day simple moving average is $2.92. The firm has a market cap of $52.84 million, a PE ratio of -0.40 and a beta of 0.87.

Dominari (NASDAQ:DOMH - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.13. Dominari had a negative return on equity of 235.37% and a negative net margin of 51.61%.The firm had revenue of $16.79 million for the quarter, compared to analysts' expectations of $16.79 million.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Dominari in a report on Monday, July 6th. Wall Street Zen downgraded shares of Dominari from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of "Sell".

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DOMH. PFG Investments LLC increased its holdings in shares of Dominari by 36.3% during the first quarter. PFG Investments LLC now owns 14,475 shares of the company's stock valued at $47,000 after purchasing an additional 3,855 shares during the period. NewEdge Advisors LLC bought a new position in Dominari in the 4th quarter valued at about $50,000. Price T Rowe Associates Inc. MD bought a new position in Dominari in the 4th quarter valued at about $96,000. Oxford Asset Management LLP acquired a new position in Dominari during the 4th quarter valued at about $120,000. Finally, Jane Street Group LLC bought a new stake in shares of Dominari during the 2nd quarter worth about $158,000. Institutional investors and hedge funds own 42.48% of the company's stock.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.